Joel I. Sorger, MD
- Co-Director, Sarcoma Program
- Director, Pediatric Joint Replacement Surgery
- Associate Professor, UC Department of Pediatrics
- joel.sorger@cchmc.org
- Board Certified
About
Biography
My dad inspired me to become a doctor. And now, when I work with children and families, I treat them like they are part of my own family.
As a pediatric orthopedist, I specialize in caring for children with cancer and in providing joint replacement surgery.
I want families to know that I am always available to them. I make myself accessible to answer their questions or talk about whatever is on their mind.
My research focuses on cancer survival in children.
When I’m not at work I enjoy playing golf and spending time with my family.
BS: Biology, University of Richmond, VA, August 1983-May 1987.
MD: Medical College of Virginia, Richmond, VA, August 1987-May 1991.
Intern: General Surgery Intern, University of Cincinnati, Cincinnati, OH, July 1991-June 1992.
Residency: General surgery resident, University of Cincinnati College of Medicine, 1992-1993; Orthopaedic surgery resident, University of Cincinnati College of Medicine, 1994-1998.
Fellowship: Orthopaedic research fellow, Noyes-Giannestras Biomechanics Lab, University of Cincinnati Department of Aerospace Engineering, 1993-1994; Bone and Soft Tissue Sarcoma Management Fellowship (Orthopaedic Oncology), Harvard University, Massachusetts General Hospital and Boston, Children’s Hospital, August 1998-July 1999.
Certification: American Board of Orthopaedic Surgeons.
Interests
Orthopaedic oncology (sarcoma surgery) and joint replacement surgery
Services and Specialties
Orthopaedic Surgery, Hemangioma and Vascular Malformations, Sarcoma, Hip Preservation
Research Areas
Orthopaedics
Insurance Information
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Publications
ASO Author Reflections: Minimizing Time in Hospital via Bone Biopsy or Other Means. Annals of Surgical Oncology. 2023; 30:3666.
Phase 2 study of larotrectinib in children with newly diagnosed infantile fibrosarcoma (IFS): Children’s Oncology Group (COG) ADVL1823 cohort A. Journal of Clinical Oncology. 2023; 41:10008.
ASO Visual Abstract: Pediatric and Young Adult Image-Guided Percutaneous Bone Biopsy-A New Standard of Care?. Annals of Surgical Oncology. 2023; 30:3667.
Pediatric and Young Adult Image-Guided Percutaneous Bone Biopsy-A New Standard of Care?. Annals of Surgical Oncology. 2023; 30:3658-3665.
Neoadjuvant pazopanib in nonrhabdomyosarcoma soft tissue sarcomas (ARST1321): A report of major wound complications from the Children's Oncology Group and NRG Oncology. Seminars in Surgical Oncology. 2023; 127:871-881.
Comparison of Prophylactic Intravenous Antibiotic Regimens After Endoprosthetic Reconstruction for Lower Extremity Bone Tumors: A Randomized Clinical Trial. JAMA oncology. 2022; 8:345-353.
Novel ARHGAP23-FER fusion in a metastatic spindle cell-predominant neoplasm with a myofibroblastic phenotype and a sustained metabolic response to lorlatinib. Cancer. 2021; 127:4124-4130.
Implant Survival and Clinical Outcomes of Total Hip Arthroplasty in Adolescent and Young Adult Patients. 2021; 05:062-069.
A large intermuscular shoulder lipoma causing pain and weakness in an 87-year-old patient: a case report. JSES International. 2021; 5:154-157.
From the Blog
COVID-19 School Study in JAMA Tops Most-Shared Findings From July 2020
Joel I. Sorger, MD, Katherine A. Auger, MD, MSc ...8/11/2020
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2024 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey